Date published: 2025-10-11

1-800-457-3801

SCBT Portrait Logo
Seach Input

mAChR M4 Inhibitors

The class of mAChR M4 inhibitors encompasses a diverse array of chemical compounds that exert their inhibitory effects on the receptor through various mechanisms. Tropicamide, an example within this class, directly interferes with mAChR M4 by binding to its acetylcholine binding site, preventing the receptor's normal activation. This direct inhibition disrupts downstream signaling pathways associated with mAChR M4, modulating cellular responses. Additionally, methoctramine acts as a selective mAChR M4 antagonist, achieving inhibition through binding to the receptor's allosteric site, inducing conformational changes that hinder its interaction with acetylcholine. Scopolamine, another member of this class, competitively binds to the orthosteric site of mAChR M4, impeding the receptor's interaction with acetylcholine and disrupting downstream signaling pathways. These inhibitors, including pirenzepine, darifenacin, and himbacine, further contribute to the specificity of mAChR M4 modulation by targeting the receptor directly and interfering with its normal functioning. Notably, telenzepine achieves inhibition through binding to the receptor, showcasing the versatility within this chemical class.AF-DX 384, a potent and selective mAChR M4 antagonist, distinguishes itself by targeting the receptor's allosteric site, inducing conformational changes that impede acetylcholine binding. Ipratropium bromide competitively binds to the orthosteric site, disrupting the normal activation of mAChR M4 and modulating downstream signaling pathways. AQRA 741, with its selectivity for mAChR M4, binds to the receptor and interferes with acetylcholine binding, providing a targeted means of influencing receptor function. Pilocarpine introduces an indirect mechanism within this class, stimulating muscarinic receptors M1 and M3, leading to increased acetylcholine release. This, in turn, activates negative feedback mechanisms inhibiting acetylcholine release at the M4 receptor. The indirect inhibition of mAChR M4 by pilocarpine showcases the diversity of approaches within this class.

SEE ALSO...

Items 11 to 15 of 15 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Pirenzepine Dihydrochloride

29868-97-1sc-204197
100 mg
$69.00
3
(0)

Pirenzepine is a selective mAChR M4 antagonist that exerts its inhibitory effects by binding specifically to the receptor. By doing so, it interferes with the normal binding of acetylcholine, disrupting downstream signaling pathways. This interference can modulate various cellular responses and physiological processes regulated by mAChR M4, providing a targeted means of inhibiting its function.

Telenzepine dihydrochloride

147416-96-4sc-204332
sc-204332A
10 mg
25 mg
$62.00
$128.00
(0)

Telenzepine is a selective mAChR M4 antagonist that achieves inhibition by binding to the receptor and interfering with the normal binding of acetylcholine. This interference disrupts downstream signaling pathways associated with mAChR M4, influencing neurotransmission and cellular responses that depend on the proper functioning of this receptor.

Ipratropium bromide

22254-24-6sc-203606
100 mg
$83.00
3
(0)

Ipratropium bromide acts as an mAChR M4 antagonist, disrupting receptor function by competitively binding to its orthosteric site. This interference prevents acetylcholine from effectively binding to the receptor, leading to the modulation of downstream signaling pathways associated with mAChR M4.

AQ-RA 741

123548-16-3sc-203517
sc-203517A
10 mg
50 mg
$135.00
$575.00
(0)

AQRA 741 is a selective mAChR M4 antagonist that achieves inhibition by binding to the receptor and interfering with the binding of acetylcholine. This interference disrupts downstream signaling pathways associated with mAChR M4, modulating cellular responses and physiological processes that depend on the normal functioning of this receptor.

Pilocarpine

92-13-7sc-479256
100 mg
$250.00
1
(0)

Pilocarpine, an alkaloid, acts as an indirect inhibitor of mAChR M4 by stimulating muscarinic receptors, particularly M1 and M3, leading to increased acetylcholine release. The subsequent activation of these receptors results in negative feedback mechanisms that inhibit the release of acetylcholine at the M4 receptor.